董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Eugene A. Bauer | 男 | Director | 78 | 未披露 | 未持股 | 2020-08-24 |
| Keyoumars Saeed | 男 | Chief Executive Officer and Director | 56 | 未披露 | 未持股 | 2020-08-24 |
| Max Munn | 男 | President and Director | 75 | 40.00万美元 | 未持股 | 2020-08-24 |
| Dallas C. Hack | 男 | Director | 67 | 未披露 | 未持股 | 2020-08-24 |
| Eugene E. Burleson | 男 | Director | 79 | 未披露 | 未持股 | 2020-08-24 |
| Alastair Clemow | 男 | Director | 69 | 未披露 | 未持股 | 2020-08-24 |
| Joel Kanter | 男 | Chairman of the Board | 63 | 未披露 | 未持股 | 2020-08-24 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Keyoumars Saeed | 男 | Chief Executive Officer and Director | 56 | 未披露 | 未持股 | 2020-08-24 |
| Max Munn | 男 | President and Director | 75 | 40.00万美元 | 未持股 | 2020-08-24 |
| James L. Doyle, III | 男 | Chief Operations Officer | 52 | 未披露 | 未持股 | 2020-08-24 |
| Joseph Himy | 男 | Interim Chief Financial Officer | 51 | 未披露 | 未持股 | 2020-08-24 |
董事简历
中英对照 | 中文 | 英文- Eugene A. Bauer
-
Eugene A. Bauer，2010年8月创办本公司，自那里起担任董事，自2011年10月起，担任首席医学官。他在许多的上市及私营企业担任过董事，其中包括： Patient Safety Technologies, Inc.，2010年1月至6月；Vyteris, Inc. ，2010年2月至2012年6月。他从 2006年6月起，担任Peplin的董事；2008年10月，他成为其总裁、首席医学官，担任该职直到2009年11月它被LEO Pharma收购。2004年11月至2008年10月，他担任Neosil Inc的首席执行官，这是一个皮肤科公司，在2008年10月被Peplin收购。1993年，他参与创办Connetics，担任其董事直到2005年10月。1995-2001，他担任Stanford University School of Medicine的院长；1988-1995，担任Stanford University School of Medicine的皮肤系主席。2002年至今，他一直是School of Medicine at Stanford University的Lucy Becker荣誉教授。另外，他还是Medgenics, Inc.、Dr. Tattoff, Inc.、First Wave Technologies, Inc.、Cerecor, Inc.、Kadmon Corporation, LLC的董事。之前，他曾担任以下公司的董事：Protalex, Inc.、Vyteris、Peplin、PetDRx, Inc.、Arbor Vita Corp.、Patient Safety Technologies, Inc.、MediSync Bioservices、Modigene Inc（现PROLOR Biotech）。他是受U.S. National Institutes of Health（NIH）25年资助的研究员，也曾任职于其审查小组。他曾任职于一些协会，其中包括Institute of Medicine of the National Academy of Sciences。他在Northwestern University获得医学学士学位、医学博士学位。
Eugene A. Bauer is a Director of the Company. In 2010 Dr. Bauer co-founded Dermira, a publicly traded specialty biopharmaceutical company acquired by Eli Lilly and Company in 2020. Dr. Bauer served as Chief Medical Officer of Dermira, a wholly-owned subsidiary of Lilly, through March 2020. Prior to founding Dermira, Dr. Bauer served as Director, President and Chief Medical Officer of Pelpin, Inc., a publicly traded specialty pharmaceutical company, from 2008 to 2010. Dr. Bauer served as Chief Executive Officer of Neosil, Inc., a specialty pharmaceutical company, from 2004 to 2008 and he co-founded and served as a member of the board of directors at Connetics, a publicly traded specialty pharmaceutical company, from 1990 to 2006. Prior to initiating his career in industry, Dr. Bauer served as Dean of Stanford University School of Medicine from 1995 to 2001 and as Chair of the Department of Dermatology at Stanford University School of Medicine from 1988 to 1995. Dr. Bauer is Professor Emeritus at Stanford University School of Medicine, a position he has held since 2002. Dr. Bauer was a U.S. National Institutes of Health “NIH”-funded investigator for 25 years and has served on review groups and Councils for the NIH. Dr. Bauer has served on the boards of directors of a number of public and private companies, including Aevi Genomic Medicine, Inc. (formerly Medgenics, Inc.), First Wave Technologies, Inc., and Kadmon Holdings, Inc. He is member of numerous honorific societies, including the National Academy of Medicine. Dr. Bauer received his B.S. in medicine from Northwestern University and his M.D. from Northwestern University Medical School. - Eugene A. Bauer，2010年8月创办本公司，自那里起担任董事，自2011年10月起，担任首席医学官。他在许多的上市及私营企业担任过董事，其中包括： Patient Safety Technologies, Inc.，2010年1月至6月；Vyteris, Inc. ，2010年2月至2012年6月。他从 2006年6月起，担任Peplin的董事；2008年10月，他成为其总裁、首席医学官，担任该职直到2009年11月它被LEO Pharma收购。2004年11月至2008年10月，他担任Neosil Inc的首席执行官，这是一个皮肤科公司，在2008年10月被Peplin收购。1993年，他参与创办Connetics，担任其董事直到2005年10月。1995-2001，他担任Stanford University School of Medicine的院长；1988-1995，担任Stanford University School of Medicine的皮肤系主席。2002年至今，他一直是School of Medicine at Stanford University的Lucy Becker荣誉教授。另外，他还是Medgenics, Inc.、Dr. Tattoff, Inc.、First Wave Technologies, Inc.、Cerecor, Inc.、Kadmon Corporation, LLC的董事。之前，他曾担任以下公司的董事：Protalex, Inc.、Vyteris、Peplin、PetDRx, Inc.、Arbor Vita Corp.、Patient Safety Technologies, Inc.、MediSync Bioservices、Modigene Inc（现PROLOR Biotech）。他是受U.S. National Institutes of Health（NIH）25年资助的研究员，也曾任职于其审查小组。他曾任职于一些协会，其中包括Institute of Medicine of the National Academy of Sciences。他在Northwestern University获得医学学士学位、医学博士学位。
- Eugene A. Bauer is a Director of the Company. In 2010 Dr. Bauer co-founded Dermira, a publicly traded specialty biopharmaceutical company acquired by Eli Lilly and Company in 2020. Dr. Bauer served as Chief Medical Officer of Dermira, a wholly-owned subsidiary of Lilly, through March 2020. Prior to founding Dermira, Dr. Bauer served as Director, President and Chief Medical Officer of Pelpin, Inc., a publicly traded specialty pharmaceutical company, from 2008 to 2010. Dr. Bauer served as Chief Executive Officer of Neosil, Inc., a specialty pharmaceutical company, from 2004 to 2008 and he co-founded and served as a member of the board of directors at Connetics, a publicly traded specialty pharmaceutical company, from 1990 to 2006. Prior to initiating his career in industry, Dr. Bauer served as Dean of Stanford University School of Medicine from 1995 to 2001 and as Chair of the Department of Dermatology at Stanford University School of Medicine from 1988 to 1995. Dr. Bauer is Professor Emeritus at Stanford University School of Medicine, a position he has held since 2002. Dr. Bauer was a U.S. National Institutes of Health “NIH”-funded investigator for 25 years and has served on review groups and Councils for the NIH. Dr. Bauer has served on the boards of directors of a number of public and private companies, including Aevi Genomic Medicine, Inc. (formerly Medgenics, Inc.), First Wave Technologies, Inc., and Kadmon Holdings, Inc. He is member of numerous honorific societies, including the National Academy of Medicine. Dr. Bauer received his B.S. in medicine from Northwestern University and his M.D. from Northwestern University Medical School.
- Keyoumars Saeed
-
Keyoumars Saeed是我们的首席执行官。一位经验丰富的首席执行官和高级执行官，在他的领导下，在销售、营销和运营发展、战略规划和业务发展方面的成就记录。Saeed先生于2011年至2020年6月担任Ubiquity LLC的首席执行官，在那里他为国家精神健康创新中心NMHIC提供建议，并与CU Innovations合作建立业务伙伴关系，并与其技术创新网络（TIN）合作开发虚拟和增强现实，以进行干预和培训协议，并在科罗拉多大学安舒茨医学中心。此前，Saeed先生于2016年创立了Vital Neuro，Inc.，并于2016年2月至2019年11月担任首席执行官兼董事，Vital Neuro，Inc.将机器学习，云技术集成在封闭反馈系统中，并且是基于证据的，证明服务缓解员工的压力，个性化的15分钟每天会话到耳机通过应用程序到公司的订户基础。在此之前，直到2015年底，赛义德在比尔盖茨（Bill Gates）旗下的Kymeta Corporation工作了三年半，担任战略与发展执行副总裁，为联网汽车战略创造市场途径，采购和确保独特的原材料以及行业关系和合作伙伴关系。在几家较小的初创公司中，Saeed先生于2004年共同创立了Open Range Communications，为美国农村和服务不足的社区提供宽带。2001年，Saeed先生在T-Mobile USA推出第一个蜂窝黑莓手机方面发挥了重要作用，在那里他是2001年向市场推出第一个融合语音和数据的设备的先锋团队的一员。他在AT&T Wireless Advanced Services Organization工作，介绍CDPD和融合无线数据直到1999年。Saeed先生在丹佛大学（University of Denver）获得商法和经济学学士学位。
Keyoumars Saeed is our Chief Executive Officer. A seasoned CEO and senior executive, under his leadership, record of achievement in sales, marketing and operations development, strategic planning, and business development. Mr. Saeed was CEO of Ubiquity LLC from 2011 until June of 2020 where he advised the National Mental Health Innovation Center NMHIC and worked with CU Innovations on business partnerships and co development with their technology innovation network (TIN) on virtual and augmented reality to conduct interventions and training protocols and at the University of Colorado Anschutz Medical Center. Previously, Mr. Saeed founded Vital Neuro, Inc. in 2016 and was CEO and a Director from February 2016 until November of 2019 Vital Neuro, Inc. converged machine learning, cloud technologies in a closed feedback system and is an evidence based, proven service relieving employee stress with a personalized 15 minute daily session to a headphone through an app to company subscriber base. Prior to that and until the end of 2015 Mr. Saeed spent three and a half years at Kymeta Corporation, a Bill Gates company, as the EVP of Strategy and development creating a market approach to the connected car strategy, sourcing and securing unique raw materials and industry relations and partnerships. Among several smaller startups, Mr. Saeed Co-founded Open Range Communications in 2004 to deliver broadband to rural and underserved communities in the US. In 2001 Mr. Saeed was instrumental in the launch of the first cellular Blackberry at T-Mobile USA where he was part of the pioneering team introducing the first device converging voice and data to the market in 2001. He spent the worked at AT&T wireless advanced services organization introducing CDPD and converged wireless data through 1999. Mr. Saeed has a BSBA in Business Law and Economics from University of Denver. - Keyoumars Saeed是我们的首席执行官。一位经验丰富的首席执行官和高级执行官，在他的领导下，在销售、营销和运营发展、战略规划和业务发展方面的成就记录。Saeed先生于2011年至2020年6月担任Ubiquity LLC的首席执行官，在那里他为国家精神健康创新中心NMHIC提供建议，并与CU Innovations合作建立业务伙伴关系，并与其技术创新网络（TIN）合作开发虚拟和增强现实，以进行干预和培训协议，并在科罗拉多大学安舒茨医学中心。此前，Saeed先生于2016年创立了Vital Neuro，Inc.，并于2016年2月至2019年11月担任首席执行官兼董事，Vital Neuro，Inc.将机器学习，云技术集成在封闭反馈系统中，并且是基于证据的，证明服务缓解员工的压力，个性化的15分钟每天会话到耳机通过应用程序到公司的订户基础。在此之前，直到2015年底，赛义德在比尔盖茨（Bill Gates）旗下的Kymeta Corporation工作了三年半，担任战略与发展执行副总裁，为联网汽车战略创造市场途径，采购和确保独特的原材料以及行业关系和合作伙伴关系。在几家较小的初创公司中，Saeed先生于2004年共同创立了Open Range Communications，为美国农村和服务不足的社区提供宽带。2001年，Saeed先生在T-Mobile USA推出第一个蜂窝黑莓手机方面发挥了重要作用，在那里他是2001年向市场推出第一个融合语音和数据的设备的先锋团队的一员。他在AT&T Wireless Advanced Services Organization工作，介绍CDPD和融合无线数据直到1999年。Saeed先生在丹佛大学（University of Denver）获得商法和经济学学士学位。
- Keyoumars Saeed is our Chief Executive Officer. A seasoned CEO and senior executive, under his leadership, record of achievement in sales, marketing and operations development, strategic planning, and business development. Mr. Saeed was CEO of Ubiquity LLC from 2011 until June of 2020 where he advised the National Mental Health Innovation Center NMHIC and worked with CU Innovations on business partnerships and co development with their technology innovation network (TIN) on virtual and augmented reality to conduct interventions and training protocols and at the University of Colorado Anschutz Medical Center. Previously, Mr. Saeed founded Vital Neuro, Inc. in 2016 and was CEO and a Director from February 2016 until November of 2019 Vital Neuro, Inc. converged machine learning, cloud technologies in a closed feedback system and is an evidence based, proven service relieving employee stress with a personalized 15 minute daily session to a headphone through an app to company subscriber base. Prior to that and until the end of 2015 Mr. Saeed spent three and a half years at Kymeta Corporation, a Bill Gates company, as the EVP of Strategy and development creating a market approach to the connected car strategy, sourcing and securing unique raw materials and industry relations and partnerships. Among several smaller startups, Mr. Saeed Co-founded Open Range Communications in 2004 to deliver broadband to rural and underserved communities in the US. In 2001 Mr. Saeed was instrumental in the launch of the first cellular Blackberry at T-Mobile USA where he was part of the pioneering team introducing the first device converging voice and data to the market in 2001. He spent the worked at AT&T wireless advanced services organization introducing CDPD and converged wireless data through 1999. Mr. Saeed has a BSBA in Business Law and Economics from University of Denver.
- Max Munn
-
Max Munn是公司的总裁和董事，也是Munn Works的首席执行官。Mr.Munn在Munn Works担任该职位超过20年。Munn先生也是Dieu Donne Inc.的联合主席，该公司是一家非营利性的，世界公认的领先工作室，在艺术制作中使用尺寸，手工造纸。Munn先生从1961年到1966年就读于麻省理工学院化学和建筑专业，并获得建筑学学士学位。Munn先生还从1966年到1968年在哥伦比亚大学（Columbia University）攻读研究生课程，并获得建筑史博士学位。
Max Munn is the President and a director of the Company and is also CEO of Munn Works. Mr. Munn has held this position at Munn Works for over 20 years. Mr. Munn is also Co-chairman of Dieu Donne Inc., a not-for-profit and a leading, world recognized atelier wherein dimensional, handmade paper is utilized in the making of art. Mr. Munn attended MIT from 1961-1966 majored in chemistry and architecture; and received a Bachelor’s of Architecture degree. Mr. Munn also attended Columbia University for post-graduate studies from 1966-1968 working toward a Ph.D. in architectural history. - Max Munn是公司的总裁和董事，也是Munn Works的首席执行官。Mr.Munn在Munn Works担任该职位超过20年。Munn先生也是Dieu Donne Inc.的联合主席，该公司是一家非营利性的，世界公认的领先工作室，在艺术制作中使用尺寸，手工造纸。Munn先生从1961年到1966年就读于麻省理工学院化学和建筑专业，并获得建筑学学士学位。Munn先生还从1966年到1968年在哥伦比亚大学（Columbia University）攻读研究生课程，并获得建筑史博士学位。
- Max Munn is the President and a director of the Company and is also CEO of Munn Works. Mr. Munn has held this position at Munn Works for over 20 years. Mr. Munn is also Co-chairman of Dieu Donne Inc., a not-for-profit and a leading, world recognized atelier wherein dimensional, handmade paper is utilized in the making of art. Mr. Munn attended MIT from 1961-1966 majored in chemistry and architecture; and received a Bachelor’s of Architecture degree. Mr. Munn also attended Columbia University for post-graduate studies from 1966-1968 working toward a Ph.D. in architectural history.
- Dallas C. Hack
-
Dallas C.Hack是公司的董事。他是一般预防医学和公共卫生的委员会认证和美国军事公共卫生学院的研究员。从2008年到2014年，他领导军队的创伤研究，负责超过20亿美元的赠款。他曾在Operations Permaning Freedom和Iraq Freedom担任战略层面的指挥外科医生。他曾担任多个军事医疗领导职位，包括北约总部梦百合设施指挥官，以及在“持久自由行动”和“伊拉克自由行动”期间担任战略级别的指挥外科医生。科尔·哈克获得了许多军事奖项，包括铜星勋章、两个功勋军团勋章，并被选为医学功勋军事勋章的杰出成员。1972年获安德鲁斯大学文学学士学位，1995年获约翰霍普金斯大学硕士学位，1976年获洛玛琳达大学医学博士学位，2004年获美国陆军战争学院硕士学位以及医学管理认证委员会CPE-1997年他于2015年5月被Loma Linda University认可为年度杰出校友。Hack博士在匹兹堡大学（University of Pittsburgh）医学院担任神经外科兼职教授，并在弗吉尼亚联邦大学（Virginia Commonwealth University）物理医学与康复系担任临床副教授。在2015年从28年的兵役中退休后，Hack博士与众多生物技术和非营利组织合作，以推进医学研究并将进展过渡到改进的临床实践。
Dallas C. Hack is a Director of the Company. He is board certified in General Preventive Medicine and Public Health and a Fellow in the American College of Military Public Health. He directed trauma research for the military from 2008 to 2014 with responsibility for more than $2 billion in grant funding. He served as Command Surgeon at the strategic level during Operations Enduring Freedom and Iraqi Freedom. He held numerous military medical leadership positions including Commander of the NATO Headquarters Healthcare Facility, and Command Surgeon at the strategic level during Operations Enduring Freedom and Iraqi Freedom. COLR Hack received numerous military awards including the Bronze Star, two Legion of Merit awards, and was inducted as a Distinguished Member of the Military Order of Medical Merit. He has a BA from Andrews University -1972 an MPH from Johns Hopkins University -1995 a MD from Loma Linda University -1976 an MSS from the US Army War College -2004 and a CPE from the Certifying Commission in Medical Management -1997 He was recognized as the Distinguished Alumnus of the Year by Loma Linda University in May 2015. Dr. Hack has an appointment from the School of Medicine, University of Pittsburgh as Adjunct Professor of Neurosurgery and from Virginia Commonwealth University as an Associate Clinical Professor, Department of Physical Medicine and Rehabilitation. After retiring from 28 years of military service in 2015 Dr. Hack has worked with numerous biotechs and non-profits to advance medical research and transition the progress to improved clinical practice. - Dallas C.Hack是公司的董事。他是一般预防医学和公共卫生的委员会认证和美国军事公共卫生学院的研究员。从2008年到2014年，他领导军队的创伤研究，负责超过20亿美元的赠款。他曾在Operations Permaning Freedom和Iraq Freedom担任战略层面的指挥外科医生。他曾担任多个军事医疗领导职位，包括北约总部梦百合设施指挥官，以及在“持久自由行动”和“伊拉克自由行动”期间担任战略级别的指挥外科医生。科尔·哈克获得了许多军事奖项，包括铜星勋章、两个功勋军团勋章，并被选为医学功勋军事勋章的杰出成员。1972年获安德鲁斯大学文学学士学位，1995年获约翰霍普金斯大学硕士学位，1976年获洛玛琳达大学医学博士学位，2004年获美国陆军战争学院硕士学位以及医学管理认证委员会CPE-1997年他于2015年5月被Loma Linda University认可为年度杰出校友。Hack博士在匹兹堡大学（University of Pittsburgh）医学院担任神经外科兼职教授，并在弗吉尼亚联邦大学（Virginia Commonwealth University）物理医学与康复系担任临床副教授。在2015年从28年的兵役中退休后，Hack博士与众多生物技术和非营利组织合作，以推进医学研究并将进展过渡到改进的临床实践。
- Dallas C. Hack is a Director of the Company. He is board certified in General Preventive Medicine and Public Health and a Fellow in the American College of Military Public Health. He directed trauma research for the military from 2008 to 2014 with responsibility for more than $2 billion in grant funding. He served as Command Surgeon at the strategic level during Operations Enduring Freedom and Iraqi Freedom. He held numerous military medical leadership positions including Commander of the NATO Headquarters Healthcare Facility, and Command Surgeon at the strategic level during Operations Enduring Freedom and Iraqi Freedom. COLR Hack received numerous military awards including the Bronze Star, two Legion of Merit awards, and was inducted as a Distinguished Member of the Military Order of Medical Merit. He has a BA from Andrews University -1972 an MPH from Johns Hopkins University -1995 a MD from Loma Linda University -1976 an MSS from the US Army War College -2004 and a CPE from the Certifying Commission in Medical Management -1997 He was recognized as the Distinguished Alumnus of the Year by Loma Linda University in May 2015. Dr. Hack has an appointment from the School of Medicine, University of Pittsburgh as Adjunct Professor of Neurosurgery and from Virginia Commonwealth University as an Associate Clinical Professor, Department of Physical Medicine and Rehabilitation. After retiring from 28 years of military service in 2015 Dr. Hack has worked with numerous biotechs and non-profits to advance medical research and transition the progress to improved clinical practice.
- Eugene E. Burleson
-
Eugene E.Burleson，本公司董事。他是私人投资者，曾担任PET DRX Corporation的主席（从2005年6月到2010年7月1日），以及其首席执行官（从2008年10月到2010年7月被VCA Antech公司收购）。Burleson从2000年9月到2003年10月Healthmont Inc.被Sunlink收购担任董事。Burleson先生从2000年1月到2002年6月担任Mariner Post-Acute Network，Inc.的董事会主席。Burleson先生还担任Alterra梦百合Inc.的董事会主席，该公司是一家辅助生活设施的开发商和运营商，也是Deckers Outdoor Corporation Inc.的董事会成员。Burleson先生从1989年10月到1997年11月担任GranCare Inc.的董事会主席。此外，Burleson从1990年12月到1997年2月担任GranCare Inc.总裁和首席执行官。他于1997年2月完成GranCare公司的药房业务与Vitalink Pharmacy Services公司的合并，并成为Vitalink Pharmacy Services公司的首席执行官兼董事。Burleson先生于1997年8月辞去Vitalink Pharmacy Services的首席执行官和董事。从1986年6月到1989年3月，Burleson先生担任美国医疗国际公司（American Medical International Inc.“；AMI”；）的总裁，首席运营官兼董事，该公司是一家急性护理医院的所有者和运营商。Burleson从1981年5月到1986年6月在伦敦担任AMI&8217；s International Operations总经理。Burleson先生从1963年到1974年在伊士曼柯达（Eastman Kodak）接受早期管理培训。他毕业于East Tennessee State University，获得会计理学学士学位，并于1972年获得工商管理硕士学位。
Eugene E. Burleson is a Director of the Company. He is a private investor and was Chairman of PET DRx Corporation from June 2005 to July 1 2010 and its Chief Executive Officer from October 2008 until its acquisition by VCA Antech in July 2010. Mr. Burleson was a director of HealthMont Inc. from September 2000 until its acquisition by SunLink in October 2003. Mr. Burleson served as Chairman of the Board of Directors of Mariner Post-Acute Network, Inc. from January 2000 to June 2002. Mr. Burleson also served as Chairman of the Board of Directors of Alterra Healthcare Inc. a developer and operator of assisted living facilities and is on the Board of Deckers Outdoor Corporation Inc. Mr. Burleson served as Chairman of the Board of GranCare Inc. from October 1989 to November 1997. Additionally, Mr. Burleson served as President and Chief Executive Officer of GranCare Inc. from December 1990 to February 1997. Upon completion of the merger of GranCare’s pharmacy operations with Vitalink Pharmacy Services Inc. in February 1997 he became Chief Executive Officer and a Director of Vitalink Pharmacy Services Inc. Mr. Burleson resigned as Chief Executive Officer and Director of Vitalink Pharmacy Services in August 1997. From June 1986 to March 1989 Mr. Burleson served as President, Chief Operating Officer and a Director of American Medical International Inc. “AMI”, an owner and operator of acute care hospitals. Based in London from May 1981 to June 1986 Mr. Burleson served as Managing Director of AMI’s international operations. Mr. Burleson received his early management training at Eastman Kodak from 1963 to 1974. He graduated from East Tennessee State University with a Bachelor of Science Degree in accounting and earned an MBA degree in 1972. - Eugene E.Burleson，本公司董事。他是私人投资者，曾担任PET DRX Corporation的主席（从2005年6月到2010年7月1日），以及其首席执行官（从2008年10月到2010年7月被VCA Antech公司收购）。Burleson从2000年9月到2003年10月Healthmont Inc.被Sunlink收购担任董事。Burleson先生从2000年1月到2002年6月担任Mariner Post-Acute Network，Inc.的董事会主席。Burleson先生还担任Alterra梦百合Inc.的董事会主席，该公司是一家辅助生活设施的开发商和运营商，也是Deckers Outdoor Corporation Inc.的董事会成员。Burleson先生从1989年10月到1997年11月担任GranCare Inc.的董事会主席。此外，Burleson从1990年12月到1997年2月担任GranCare Inc.总裁和首席执行官。他于1997年2月完成GranCare公司的药房业务与Vitalink Pharmacy Services公司的合并，并成为Vitalink Pharmacy Services公司的首席执行官兼董事。Burleson先生于1997年8月辞去Vitalink Pharmacy Services的首席执行官和董事。从1986年6月到1989年3月，Burleson先生担任美国医疗国际公司（American Medical International Inc.“；AMI”；）的总裁，首席运营官兼董事，该公司是一家急性护理医院的所有者和运营商。Burleson从1981年5月到1986年6月在伦敦担任AMI&8217；s International Operations总经理。Burleson先生从1963年到1974年在伊士曼柯达（Eastman Kodak）接受早期管理培训。他毕业于East Tennessee State University，获得会计理学学士学位，并于1972年获得工商管理硕士学位。
- Eugene E. Burleson is a Director of the Company. He is a private investor and was Chairman of PET DRx Corporation from June 2005 to July 1 2010 and its Chief Executive Officer from October 2008 until its acquisition by VCA Antech in July 2010. Mr. Burleson was a director of HealthMont Inc. from September 2000 until its acquisition by SunLink in October 2003. Mr. Burleson served as Chairman of the Board of Directors of Mariner Post-Acute Network, Inc. from January 2000 to June 2002. Mr. Burleson also served as Chairman of the Board of Directors of Alterra Healthcare Inc. a developer and operator of assisted living facilities and is on the Board of Deckers Outdoor Corporation Inc. Mr. Burleson served as Chairman of the Board of GranCare Inc. from October 1989 to November 1997. Additionally, Mr. Burleson served as President and Chief Executive Officer of GranCare Inc. from December 1990 to February 1997. Upon completion of the merger of GranCare’s pharmacy operations with Vitalink Pharmacy Services Inc. in February 1997 he became Chief Executive Officer and a Director of Vitalink Pharmacy Services Inc. Mr. Burleson resigned as Chief Executive Officer and Director of Vitalink Pharmacy Services in August 1997. From June 1986 to March 1989 Mr. Burleson served as President, Chief Operating Officer and a Director of American Medical International Inc. “AMI”, an owner and operator of acute care hospitals. Based in London from May 1981 to June 1986 Mr. Burleson served as Managing Director of AMI’s international operations. Mr. Burleson received his early management training at Eastman Kodak from 1963 to 1974. He graduated from East Tennessee State University with a Bachelor of Science Degree in accounting and earned an MBA degree in 1972.
- Alastair Clemow
-
Alastair Clemow，2010年8月开始担任公司董事。他担任Regentis Biomaterials 公司总裁和首席执行官，这是一家开发软骨修复的创新材料的私人公司。之前，他在他参与创立的多家公司担任总裁和首席执行官，包括Nexgen Spine公司，该公司开发出一种人造脊椎盘，2011年被K2M公司收购；包括Gelifex Inc.公司，该公司开发了一种创新性的脊柱髓核置换植入物，2004年被Synthes Spine 公司收购；包括微创外科技术公司（Minimally Invasive Surgical Technologies），该公司开发出了一系列新的假体微创全膝关节置换术，2005年被MAKO收购。从2000年到2004年，他在Tanton科技公司（Tanton Technologies）担任负责人，这是一家向大型、中兴和早期发展阶段的公司提供新医疗器材机遇在战略和技术上的评估的组织。在那之前，他在众多岗位工作过，包括从1981年到2000年，在Johnson & Johnson 公司任职，包括Ethicon Endo-Surgery公司全球业务开发副总裁，Johnson & Johnson Professional公司新业务开发副总裁，Johnson & Johnson Orthopedics公司研究开发总监。在那些岗位上，他负责的收购和开发项目现在已经转化为Johnson & Johnson公司几十亿美元的收入。他在多家私人或上市公司担任董事，包括从2003年开始担任BioMedical Enterprises公司董事；从2007年到2012年，担任Kinetic Muscles公司董事；从2011年到2012年，担任Vyteris 公司董事；从2011年开始担任Regentis有限责任公司董事；从2005年到2010年，担任HydroCision公司董事；从2006年到2009年，担任Echo健康医疗公司董事；从2006年到2009年，担任Modigene公司（现在的PROLOR Biotech）董事；从2002年到2007年，担任Encore医疗公司董事。他持有12项美国专利，在哥伦比亚大学（Columbia University）得到财务工商管理硕士学位，在英国吉尔福德萨里大学（University of Surrey, Guildford, United Kingdom）得到冶金博士学位。
Alastair Clemow is a Director of the Company. Dr. Clemow currently serves as Chairman of Ensemble Orthopedics, an early-stage company developing an innovative pyrocarbon finger joint for the treatment for early state osteoarthritis. From 2010 to 2019 Dr. Clemow served as President and Chief Executive Officer of Regentis Biomaterials, a private company developing an innovative material for cartilage repair. He also held positions of president and chief executive officer in a number of companies that he helped found, including Nexgen Spine, Inc., which developed an artificial spinal disc; Gelifex, Inc., which developed an innovative spinal nucleus replacement implant and which was acquired in 2004 by Synthes Spine, Inc.; and Minimally Invasive Surgical Technologies, Inc., which developed a novel series of implants for minimally invasive total knee replacement and which was acquired in 2005 by MAKO Surgical Corp. From 2000 to 2004 Dr. Clemow served as Principal of Tanton Technologies, Inc., an organization that provided strategic and technical assessment of new medical device opportunities for large, mid-cap, and early-stage development companies. From 1981 to 2000 Dr. Clemow held numerous positions with Johnson & Johnson, including Vice President of Worldwide Business Development for Ethicon Endo-Surgery, Inc.; Vice President of New Business Development for Johnson & Johnson Professional, Inc.; and Director of Research and Development of Johnson & Johnson Orthopedics. In those capacities, Dr. Clemow was responsible for acquiring or developing what today represents billions of dollars of Johnson & Johnson revenue. Dr. Clemow serves or has served on the boards of numerous private and public companies including Aevi Genomics; Encore Medical; Echo Healthcare Acquisition Corp.; BioMedical Enterprises, Inc.; and Kinetic Muscles, Inc. He graduated from the University of Surrey with a Bachelor of Science Degree in metallurgy and Ph.D. in metallurgy and earned his MBA degree from Columbia University in New York. - Alastair Clemow，2010年8月开始担任公司董事。他担任Regentis Biomaterials 公司总裁和首席执行官，这是一家开发软骨修复的创新材料的私人公司。之前，他在他参与创立的多家公司担任总裁和首席执行官，包括Nexgen Spine公司，该公司开发出一种人造脊椎盘，2011年被K2M公司收购；包括Gelifex Inc.公司，该公司开发了一种创新性的脊柱髓核置换植入物，2004年被Synthes Spine 公司收购；包括微创外科技术公司（Minimally Invasive Surgical Technologies），该公司开发出了一系列新的假体微创全膝关节置换术，2005年被MAKO收购。从2000年到2004年，他在Tanton科技公司（Tanton Technologies）担任负责人，这是一家向大型、中兴和早期发展阶段的公司提供新医疗器材机遇在战略和技术上的评估的组织。在那之前，他在众多岗位工作过，包括从1981年到2000年，在Johnson & Johnson 公司任职，包括Ethicon Endo-Surgery公司全球业务开发副总裁，Johnson & Johnson Professional公司新业务开发副总裁，Johnson & Johnson Orthopedics公司研究开发总监。在那些岗位上，他负责的收购和开发项目现在已经转化为Johnson & Johnson公司几十亿美元的收入。他在多家私人或上市公司担任董事，包括从2003年开始担任BioMedical Enterprises公司董事；从2007年到2012年，担任Kinetic Muscles公司董事；从2011年到2012年，担任Vyteris 公司董事；从2011年开始担任Regentis有限责任公司董事；从2005年到2010年，担任HydroCision公司董事；从2006年到2009年，担任Echo健康医疗公司董事；从2006年到2009年，担任Modigene公司（现在的PROLOR Biotech）董事；从2002年到2007年，担任Encore医疗公司董事。他持有12项美国专利，在哥伦比亚大学（Columbia University）得到财务工商管理硕士学位，在英国吉尔福德萨里大学（University of Surrey, Guildford, United Kingdom）得到冶金博士学位。
- Alastair Clemow is a Director of the Company. Dr. Clemow currently serves as Chairman of Ensemble Orthopedics, an early-stage company developing an innovative pyrocarbon finger joint for the treatment for early state osteoarthritis. From 2010 to 2019 Dr. Clemow served as President and Chief Executive Officer of Regentis Biomaterials, a private company developing an innovative material for cartilage repair. He also held positions of president and chief executive officer in a number of companies that he helped found, including Nexgen Spine, Inc., which developed an artificial spinal disc; Gelifex, Inc., which developed an innovative spinal nucleus replacement implant and which was acquired in 2004 by Synthes Spine, Inc.; and Minimally Invasive Surgical Technologies, Inc., which developed a novel series of implants for minimally invasive total knee replacement and which was acquired in 2005 by MAKO Surgical Corp. From 2000 to 2004 Dr. Clemow served as Principal of Tanton Technologies, Inc., an organization that provided strategic and technical assessment of new medical device opportunities for large, mid-cap, and early-stage development companies. From 1981 to 2000 Dr. Clemow held numerous positions with Johnson & Johnson, including Vice President of Worldwide Business Development for Ethicon Endo-Surgery, Inc.; Vice President of New Business Development for Johnson & Johnson Professional, Inc.; and Director of Research and Development of Johnson & Johnson Orthopedics. In those capacities, Dr. Clemow was responsible for acquiring or developing what today represents billions of dollars of Johnson & Johnson revenue. Dr. Clemow serves or has served on the boards of numerous private and public companies including Aevi Genomics; Encore Medical; Echo Healthcare Acquisition Corp.; BioMedical Enterprises, Inc.; and Kinetic Muscles, Inc. He graduated from the University of Surrey with a Bachelor of Science Degree in metallurgy and Ph.D. in metallurgy and earned his MBA degree from Columbia University in New York.
- Joel Kanter
-
Joel Kanter是董事。他自2007年6月以来担任董事。他在金融服务行业工作超过30年，一直专注于为小型和中型公司提供股权和过桥融资。他担任私人投资公司Windy City, Inc.的总裁，是公开上市贸易公司Walnut Financial Services, Inc.的首席执行官和总裁。他目前在Dr. Tattoff, Inc., Magna-Lab, Inc.和Medgenics, Inc.董事会工作，以及负责一些私人问题，过去的五年里他在I-Flow Corporation, Pet DRx Corporation和Vyteris, Inc.董事会工作。他从Tulane University获得政治科学和心理学学士学位。
Joel Kanter is the Chairman of the Board of the Company. Mr. Kanter serves as President of Windy City, Inc., a privately held investment firm, since July 1986. From 1989 to November 1999 Mr. Kanter served as the President, and subsequently as the President and Chief Executive Officer of Walnut Financial Services, Inc., a publicly traded company Nasdaq: WNUT. Walnut Financial's primary business focus was the provision of various forms of financing to small business including equity financing to start-up and early stage development companies, bridge financing to small and medium-sized companies, and later stage institutional financing to mature enterprises. Tower Hill Capital bought the Company in 1999 in a transaction valued at approximately $400 million. From 1978 - 1980 Mr. Kanter served as a Legislative Assistant to former Congressman Abner J. Mikva (D-Ill.). In that position, Mr. Kanter provided support to Congressman Mikva with respect to activities related to his position on the House Judiciary Committee. In particular, Mr. Kanter was intimately involved in efforts to reform the Federal Criminal Code. Mikva subsequently became the Chief Judge of the U.S. Court of Appeals for the District of Columbia Circuit, and then served as White House Counsel to President Clinton. From 1980 - 1983 Mr. Kanter served as Special Assistant to the National Association of Attorneys General. In that position, he represented the interests of the State Attorneys General in Washington, D.C. in the criminal justice and environmental arenas. Mr. Kanter serves on the Board of Directors of one currently public company, Magna-Labs, Inc., which was formerly involved in the development of a cardiac MRI device. Mr. Kanter also serves on the boards of several private biotechnology companies. Mr. Kanter is a National Association of Corporate Directors "Governance Fellow." Mr. Kanter is a current Trustee Emeritus and past President of the Board of Trustees of The Langley School in McLean, Virginia, a former Trustee at the Georgetown Day School in Washington, D.C., and a former Trustee of the Union Institute & University, the Country's first Online University. - Joel Kanter是董事。他自2007年6月以来担任董事。他在金融服务行业工作超过30年，一直专注于为小型和中型公司提供股权和过桥融资。他担任私人投资公司Windy City, Inc.的总裁，是公开上市贸易公司Walnut Financial Services, Inc.的首席执行官和总裁。他目前在Dr. Tattoff, Inc., Magna-Lab, Inc.和Medgenics, Inc.董事会工作，以及负责一些私人问题，过去的五年里他在I-Flow Corporation, Pet DRx Corporation和Vyteris, Inc.董事会工作。他从Tulane University获得政治科学和心理学学士学位。
- Joel Kanter is the Chairman of the Board of the Company. Mr. Kanter serves as President of Windy City, Inc., a privately held investment firm, since July 1986. From 1989 to November 1999 Mr. Kanter served as the President, and subsequently as the President and Chief Executive Officer of Walnut Financial Services, Inc., a publicly traded company Nasdaq: WNUT. Walnut Financial's primary business focus was the provision of various forms of financing to small business including equity financing to start-up and early stage development companies, bridge financing to small and medium-sized companies, and later stage institutional financing to mature enterprises. Tower Hill Capital bought the Company in 1999 in a transaction valued at approximately $400 million. From 1978 - 1980 Mr. Kanter served as a Legislative Assistant to former Congressman Abner J. Mikva (D-Ill.). In that position, Mr. Kanter provided support to Congressman Mikva with respect to activities related to his position on the House Judiciary Committee. In particular, Mr. Kanter was intimately involved in efforts to reform the Federal Criminal Code. Mikva subsequently became the Chief Judge of the U.S. Court of Appeals for the District of Columbia Circuit, and then served as White House Counsel to President Clinton. From 1980 - 1983 Mr. Kanter served as Special Assistant to the National Association of Attorneys General. In that position, he represented the interests of the State Attorneys General in Washington, D.C. in the criminal justice and environmental arenas. Mr. Kanter serves on the Board of Directors of one currently public company, Magna-Labs, Inc., which was formerly involved in the development of a cardiac MRI device. Mr. Kanter also serves on the boards of several private biotechnology companies. Mr. Kanter is a National Association of Corporate Directors "Governance Fellow." Mr. Kanter is a current Trustee Emeritus and past President of the Board of Trustees of The Langley School in McLean, Virginia, a former Trustee at the Georgetown Day School in Washington, D.C., and a former Trustee of the Union Institute & University, the Country's first Online University.
高管简历
中英对照 | 中文 | 英文- Keyoumars Saeed
Keyoumars Saeed是我们的首席执行官。一位经验丰富的首席执行官和高级执行官，在他的领导下，在销售、营销和运营发展、战略规划和业务发展方面的成就记录。Saeed先生于2011年至2020年6月担任Ubiquity LLC的首席执行官，在那里他为国家精神健康创新中心NMHIC提供建议，并与CU Innovations合作建立业务伙伴关系，并与其技术创新网络（TIN）合作开发虚拟和增强现实，以进行干预和培训协议，并在科罗拉多大学安舒茨医学中心。此前，Saeed先生于2016年创立了Vital Neuro，Inc.，并于2016年2月至2019年11月担任首席执行官兼董事，Vital Neuro，Inc.将机器学习，云技术集成在封闭反馈系统中，并且是基于证据的，证明服务缓解员工的压力，个性化的15分钟每天会话到耳机通过应用程序到公司的订户基础。在此之前，直到2015年底，赛义德在比尔盖茨（Bill Gates）旗下的Kymeta Corporation工作了三年半，担任战略与发展执行副总裁，为联网汽车战略创造市场途径，采购和确保独特的原材料以及行业关系和合作伙伴关系。在几家较小的初创公司中，Saeed先生于2004年共同创立了Open Range Communications，为美国农村和服务不足的社区提供宽带。2001年，Saeed先生在T-Mobile USA推出第一个蜂窝黑莓手机方面发挥了重要作用，在那里他是2001年向市场推出第一个融合语音和数据的设备的先锋团队的一员。他在AT&T Wireless Advanced Services Organization工作，介绍CDPD和融合无线数据直到1999年。Saeed先生在丹佛大学（University of Denver）获得商法和经济学学士学位。
Keyoumars Saeed is our Chief Executive Officer. A seasoned CEO and senior executive, under his leadership, record of achievement in sales, marketing and operations development, strategic planning, and business development. Mr. Saeed was CEO of Ubiquity LLC from 2011 until June of 2020 where he advised the National Mental Health Innovation Center NMHIC and worked with CU Innovations on business partnerships and co development with their technology innovation network (TIN) on virtual and augmented reality to conduct interventions and training protocols and at the University of Colorado Anschutz Medical Center. Previously, Mr. Saeed founded Vital Neuro, Inc. in 2016 and was CEO and a Director from February 2016 until November of 2019 Vital Neuro, Inc. converged machine learning, cloud technologies in a closed feedback system and is an evidence based, prven service relieving employee stress with a personalized 15 minute daily session to a headphone through an app to company subscriber base. Prior to that and until the end of 2015 Mr. Saeed spent three and a half years at Kymeta Corporation, a Bill Gates company, as the EVP of Strategy and development creating a market approach to the connected car strategy, sourcing and securing unique raw materials and industry relations and partnerships. Among several smaller startups, Mr. Saeed Co-founded Open Range Communications in 2004 to deliver broadband to rural and underserved communities in the US. In 2001 Mr. Saeed was instrumental in the launch of the first cellular Blackberry at T-Mobile USA where he was part of the pioneering team introducing the first device converging voice and data to the market in 2001. He spent the worked at AT&T wireless advanced services organization introducing CDPD and converged wireless data through 1999. Mr. Saeed has a BSBA in Business Law and Economics from University of Denver.- Keyoumars Saeed是我们的首席执行官。一位经验丰富的首席执行官和高级执行官，在他的领导下，在销售、营销和运营发展、战略规划和业务发展方面的成就记录。Saeed先生于2011年至2020年6月担任Ubiquity LLC的首席执行官，在那里他为国家精神健康创新中心NMHIC提供建议，并与CU Innovations合作建立业务伙伴关系，并与其技术创新网络（TIN）合作开发虚拟和增强现实，以进行干预和培训协议，并在科罗拉多大学安舒茨医学中心。此前，Saeed先生于2016年创立了Vital Neuro，Inc.，并于2016年2月至2019年11月担任首席执行官兼董事，Vital Neuro，Inc.将机器学习，云技术集成在封闭反馈系统中，并且是基于证据的，证明服务缓解员工的压力，个性化的15分钟每天会话到耳机通过应用程序到公司的订户基础。在此之前，直到2015年底，赛义德在比尔盖茨（Bill Gates）旗下的Kymeta Corporation工作了三年半，担任战略与发展执行副总裁，为联网汽车战略创造市场途径，采购和确保独特的原材料以及行业关系和合作伙伴关系。在几家较小的初创公司中，Saeed先生于2004年共同创立了Open Range Communications，为美国农村和服务不足的社区提供宽带。2001年，Saeed先生在T-Mobile USA推出第一个蜂窝黑莓手机方面发挥了重要作用，在那里他是2001年向市场推出第一个融合语音和数据的设备的先锋团队的一员。他在AT&T Wireless Advanced Services Organization工作，介绍CDPD和融合无线数据直到1999年。Saeed先生在丹佛大学（University of Denver）获得商法和经济学学士学位。
- Keyoumars Saeed is our Chief Executive Officer. A seasoned CEO and senior executive, under his leadership, record of achievement in sales, marketing and operations development, strategic planning, and business development. Mr. Saeed was CEO of Ubiquity LLC from 2011 until June of 2020 where he advised the National Mental Health Innovation Center NMHIC and worked with CU Innovations on business partnerships and co development with their technology innovation network (TIN) on virtual and augmented reality to conduct interventions and training protocols and at the University of Colorado Anschutz Medical Center. Previously, Mr. Saeed founded Vital Neuro, Inc. in 2016 and was CEO and a Director from February 2016 until November of 2019 Vital Neuro, Inc. converged machine learning, cloud technologies in a closed feedback system and is an evidence based, prven service relieving employee stress with a personalized 15 minute daily session to a headphone through an app to company subscriber base. Prior to that and until the end of 2015 Mr. Saeed spent three and a half years at Kymeta Corporation, a Bill Gates company, as the EVP of Strategy and development creating a market approach to the connected car strategy, sourcing and securing unique raw materials and industry relations and partnerships. Among several smaller startups, Mr. Saeed Co-founded Open Range Communications in 2004 to deliver broadband to rural and underserved communities in the US. In 2001 Mr. Saeed was instrumental in the launch of the first cellular Blackberry at T-Mobile USA where he was part of the pioneering team introducing the first device converging voice and data to the market in 2001. He spent the worked at AT&T wireless advanced services organization introducing CDPD and converged wireless data through 1999. Mr. Saeed has a BSBA in Business Law and Economics from University of Denver.
- Max Munn
Max Munn是公司的总裁和董事，也是Munn Works的首席执行官。Mr.Munn在Munn Works担任该职位超过20年。Munn先生也是Dieu Donne Inc.的联合主席，该公司是一家非营利性的，世界公认的领先工作室，在艺术制作中使用尺寸，手工造纸。Munn先生从1961年到1966年就读于麻省理工学院化学和建筑专业，并获得建筑学学士学位。Munn先生还从1966年到1968年在哥伦比亚大学（Columbia University）攻读研究生课程，并获得建筑史博士学位。
Max Munn is the President and a director of the Company and is also CEO of Munn Works. Mr. Munn has held this position at Munn Works for over 20 years. Mr. Munn is also Co-chairman of Dieu Donne Inc., a not-for-profit and a leading, world recognized atelier wherein dimensional, handmade paper is utilized in the making of art. Mr. Munn attended MIT from 1961-1966 majored in chemistry and architecture; and received a Bachelor’s of Architecture degree. Mr. Munn also attended Columbia University for post-graduate studies from 1966-1968 working toward a Ph.D. in architectural history.- Max Munn是公司的总裁和董事，也是Munn Works的首席执行官。Mr.Munn在Munn Works担任该职位超过20年。Munn先生也是Dieu Donne Inc.的联合主席，该公司是一家非营利性的，世界公认的领先工作室，在艺术制作中使用尺寸，手工造纸。Munn先生从1961年到1966年就读于麻省理工学院化学和建筑专业，并获得建筑学学士学位。Munn先生还从1966年到1968年在哥伦比亚大学（Columbia University）攻读研究生课程，并获得建筑史博士学位。
- Max Munn is the President and a director of the Company and is also CEO of Munn Works. Mr. Munn has held this position at Munn Works for over 20 years. Mr. Munn is also Co-chairman of Dieu Donne Inc., a not-for-profit and a leading, world recognized atelier wherein dimensional, handmade paper is utilized in the making of art. Mr. Munn attended MIT from 1961-1966 majored in chemistry and architecture; and received a Bachelor’s of Architecture degree. Mr. Munn also attended Columbia University for post-graduate studies from 1966-1968 working toward a Ph.D. in architectural history.
- James L. Doyle, III
James L.Doyle，III是我们的首席运营官。Doyle先生自2018年4月起担任MobilityNext的董事会成员。Doyle先生创立了MobilityNext，这是一家非营利组织，使公共和私人实体共同解决世界上最具挑战性的运输和流动性挑战。Doyle先生于2009年11月至2018年3月担任松下企业解决方案公司“PESC”的总裁。PESC是一家价值4.5亿美元的解决方案和工程公司，主要专注于北美，但在亚洲和欧洲的客户有限。这家公司为松下在体育娱乐、能源、智慧城市行业的全球客户打造了复杂的解决方案。他的客户从费城老鹰队到米高梅，再到美国政府。加入Panasonic之前，Doyle从1996年6月到2009年10月担任IBM Global Business Services咨询合伙人。Doyle先生领导其北美电子行业解决方案部门，这是在IBM工作的13年中的最后一个角色。Doyle先生还在美国海军陆战队（US Marine Corps）担任军官，参与索马里的恢复希望行动（Operation Restore Hope）。Doyle先生于1996年获得印第安纳大学（Indiana University）的市场营销与决策与信息系统工商管理硕士学位，并于1990年获得雪城大学（Syracuse University）的市场营销学士学位。
James L. Doyle, III is our Chief Operations Officer. Mr. Doyle has served on the board of Mobilitynext since April of 2018. Mr. Doyle founded Mobilitynext, a nonprofit organization that makes public and private entities together to solve the world's most challenging transportation and mobility challenges. Mr. Doyle was the President of Panasonic Enterprise Solutions Company "PESC" from November 2009 to March of 2018. PESC is a $450 million solution and engineering company focused primarily on North America, but with limited clients in Asia and Europe. This company built complex solutions for Panasonic's global customers in sports and entertainment, energy, and smart city industries. His clients ranged from the Philadelphia Eagles to MGM to the US Government. Before joining Panasonic, Mr. Doyle was a Consulting Partner with IBM Global Business Services from June 1996 until October 2009. Mr. Doyle lead its North American Electronics industry solutions unit, the final role in a thirteen-year span with IBM. Mr. Doyle also served as an Officer in the US Marine Corps, participating in Operation Restore Hope in Somalia. Mr. Doyle has an MBA in Marketing and Decision & Information Systems from Indiana University in 1996 and a BS in Marketing from Syracuse University in 1990.- James L.Doyle，III是我们的首席运营官。Doyle先生自2018年4月起担任MobilityNext的董事会成员。Doyle先生创立了MobilityNext，这是一家非营利组织，使公共和私人实体共同解决世界上最具挑战性的运输和流动性挑战。Doyle先生于2009年11月至2018年3月担任松下企业解决方案公司“PESC”的总裁。PESC是一家价值4.5亿美元的解决方案和工程公司，主要专注于北美，但在亚洲和欧洲的客户有限。这家公司为松下在体育娱乐、能源、智慧城市行业的全球客户打造了复杂的解决方案。他的客户从费城老鹰队到米高梅，再到美国政府。加入Panasonic之前，Doyle从1996年6月到2009年10月担任IBM Global Business Services咨询合伙人。Doyle先生领导其北美电子行业解决方案部门，这是在IBM工作的13年中的最后一个角色。Doyle先生还在美国海军陆战队（US Marine Corps）担任军官，参与索马里的恢复希望行动（Operation Restore Hope）。Doyle先生于1996年获得印第安纳大学（Indiana University）的市场营销与决策与信息系统工商管理硕士学位，并于1990年获得雪城大学（Syracuse University）的市场营销学士学位。
- James L. Doyle, III is our Chief Operations Officer. Mr. Doyle has served on the board of Mobilitynext since April of 2018. Mr. Doyle founded Mobilitynext, a nonprofit organization that makes public and private entities together to solve the world's most challenging transportation and mobility challenges. Mr. Doyle was the President of Panasonic Enterprise Solutions Company "PESC" from November 2009 to March of 2018. PESC is a $450 million solution and engineering company focused primarily on North America, but with limited clients in Asia and Europe. This company built complex solutions for Panasonic's global customers in sports and entertainment, energy, and smart city industries. His clients ranged from the Philadelphia Eagles to MGM to the US Government. Before joining Panasonic, Mr. Doyle was a Consulting Partner with IBM Global Business Services from June 1996 until October 2009. Mr. Doyle lead its North American Electronics industry solutions unit, the final role in a thirteen-year span with IBM. Mr. Doyle also served as an Officer in the US Marine Corps, participating in Operation Restore Hope in Somalia. Mr. Doyle has an MBA in Marketing and Decision & Information Systems from Indiana University in 1996 and a BS in Marketing from Syracuse University in 1990.
- Joseph Himy
约瑟夫·希米是我们的临时首席财务官。Himy自2011年8月起担任CFO Squad（一家金融和商业咨询公司，主要为上市公司提供外包CFO咨询和监管咨询服务）董事。2009年5月至2011年8月，Himy先生是Vyteris，Inc.的首席财务官，Vyteris，Inc.是美国食品和药物管理局批准的第一种活性透皮贴剂的制造商，用于抽血、静脉插管和激光消融浅表皮肤损伤引起的疼痛。2009年5月之前和2004年10月起，Himy先生在Vyteris担任多个其他职位，包括公司财务总监和财务副总裁。Himy先生在纽约城市大学布鲁克林学院（Brooklyn College of the City University of New York）获得会计学B.S.学位，是一名注册会计师。Himy先生也是Tofutti BrandsInc.独立董事，自2013年10月30日起担任其审计委员会成员。
Joseph Himy is our Interim Chief Financial Officer. Mr. Himy is a Director of The CFO Squad, a financial and business advisory firm providing outsourced CFO advisory and regulatory consulting services primarily for public companies, since August 2011. From May 2009 until August 2011 Mr. Himy was Chief Financial Officer of Vyteris, Inc., manufacturer of the first active transdermal patch approved by the U.S. Food and Drug Administration for the pain associated with blood draws, intravenous cannulations and laser ablation of superficial skin lesions. Prior to May 2009 and from October 2004 Mr. Himy held various other positions at Vyteris, including Corporate Controller and VP of Finance. Mr. Himy received a B.S. degree in Accounting from Brooklyn College of the City University of New York and is a certified public accountant. Mr. Himy is also Independent Director of Tofutti Brands Inc. and a member of its Audit Committee since October 30 2013.- 约瑟夫·希米是我们的临时首席财务官。Himy自2011年8月起担任CFO Squad（一家金融和商业咨询公司，主要为上市公司提供外包CFO咨询和监管咨询服务）董事。2009年5月至2011年8月，Himy先生是Vyteris，Inc.的首席财务官，Vyteris，Inc.是美国食品和药物管理局批准的第一种活性透皮贴剂的制造商，用于抽血、静脉插管和激光消融浅表皮肤损伤引起的疼痛。2009年5月之前和2004年10月起，Himy先生在Vyteris担任多个其他职位，包括公司财务总监和财务副总裁。Himy先生在纽约城市大学布鲁克林学院（Brooklyn College of the City University of New York）获得会计学B.S.学位，是一名注册会计师。Himy先生也是Tofutti BrandsInc.独立董事，自2013年10月30日起担任其审计委员会成员。
- Joseph Himy is our Interim Chief Financial Officer. Mr. Himy is a Director of The CFO Squad, a financial and business advisory firm providing outsourced CFO advisory and regulatory consulting services primarily for public companies, since August 2011. From May 2009 until August 2011 Mr. Himy was Chief Financial Officer of Vyteris, Inc., manufacturer of the first active transdermal patch approved by the U.S. Food and Drug Administration for the pain associated with blood draws, intravenous cannulations and laser ablation of superficial skin lesions. Prior to May 2009 and from October 2004 Mr. Himy held various other positions at Vyteris, including Corporate Controller and VP of Finance. Mr. Himy received a B.S. degree in Accounting from Brooklyn College of the City University of New York and is a certified public accountant. Mr. Himy is also Independent Director of Tofutti Brands Inc. and a member of its Audit Committee since October 30 2013.